RxDoctor Payments Data

Terri Jaggers, MD

Gastroenterology · Florence, SCNPI 1336158658

Payments from drug & device makers

$1,906in general payments, 2019–2025

Across 88 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$653
  • Steris Corporation$257
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$217
  • Takeda Pharmaceuticals U.S.A., Inc.$189
  • Johnson & Johnson$169
  • ERBE USA Inc$100
  • plus $320 from 15 others

What the payments were for

  • Food & beverage$1,906100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,906 in reported general payments places this provider in the 35th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$94,412
Medicare patients
486
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide48$37,708
CreonLipase/Protease/Amylase20$14,766
Sucralfate29$9,392
Mesalamine33$7,796
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl347$5,633
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates61$4,361
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl244$3,946
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,097
Lactulose30$1,011
Omeprazole48$707
Balsalazide Disodium12$631
Famotidine40$478
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg20$415
Pantoprazole Sodium42$245
Ondansetron Hcl12$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$653$52,47468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →